Biocartis Announces Market Release of SeptiCyte® RAPID test on Idylla™ Kumar Jeetendra | October 7, 2020 Mechelen, Belgium, 6 October 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the market release of SeptiCyte® RAPID on Idylla™ as a CE-marked IVD test. SeptiCyte® RAPID is a host-response test1 that distinguishes sepsis from non-infectious systemic inflammation in patients suspected of sepsis and …
Glenmark Pharma gets USFDA gesture to showcase drug for backsliding numerous sclerosis Kumar Jeetendra | October 7, 2020 Drug major Glenmark Pharma on Wednesday said it has received final approval from the US health regulator for Dimethyl Fumarate delayed-release capsules, used for treatment of relapsing forms of multiple sclerosis in adults. Quoting IQVIA sales data for the 12 month period ending August 2020, Glenmark said Tecfidera delayed-release capsules, 120 mg and 240 mg, …
Lupin gets USFDA gesture to showcase drug for treating backsliding various sclerosis Kumar Jeetendra | October 6, 2020 The company has received approval from the United States Food and Drug Administration (USFDA) to advertise its own Dimethyl Fumarate delayed-release capsules in the strengths of 120 mg and 240 mg, Lupin said in a statement. The item is a generic version of Biogen Inc”s Tecfidera delayed-release capsules at the same strengths, it added. The …
Moderna antibody preliminary temporary workers neglect to select enough minorities, inciting lull Kumar Jeetendra | October 6, 2020 Private contractors hired by Moderna Inc to recruit volunteers for its coronavirus vaccine trial failed to enrol enough Black, Latino and Native American participants to ascertain how well the vaccine works in such populations, company executives and vaccine researchers told Reuters. To compensate for the shortfall, Moderna slowed registration of its late-stage trial and educated …
Panthera Biopartners concludes Series A financing with Gresham House Ventures as major investor Kumar Jeetendra | October 2, 2020 Panthera Biopartners (Panthera) has completed a Series A funding round with Gresham House Ventures as a major investor. The capital raised will enable Panthera to further build out its network of clinical trial sites across the UK and overseas and increase its team of clinical trial experts in serving both pharma and patients. Panthera Chairman …
Moderna COVID-19 antibody seems safe, gives indications of working in more seasoned grown-ups: Study Kumar Jeetendra | September 30, 2020 Results from an early safety study of Moderna Inc’s coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those found in younger adults, with side effects about on par with high-dose flu shots, researchers said on Tuesday. The study, published in the New England Journal of Medicine, offers …
GlaxoSmithKline CEO hopeful COVID-19 immunization generally accessible in 2021 Kumar Jeetendra | September 30, 2020 The chief executive of GlaxoSmithKline, the world’s largest maker of vaccines, said she was convinced that the industry will have the ability to make an immunisation against COVID-19 widely available next year. “I share the optimism that we’ll have solutions next year. The challenge here is getting into the scale that’s required,” GSK CEO Emma …
Johnson and Johnson’s COVID-19 immunization produces solid invulnerable reaction in early preliminary Kumar Jeetendra | September 26, 2020 Pharmaceutical giant Johnson & Johnson’s experimental COVID-19 vaccine has produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, in accordance with the data published on September 25. “The data demonstrate that a single dose of COVID-19 vaccine, Ad26.COV2.S, induced a powerful neutralising antibody response in nearly all participants aged …
Zydus Cadila gets USFDA gesture for numerous sclerosis treatment drug Kumar Jeetendra | September 26, 2020 Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Dimethyl Fumarate delayed release capsules, (Tecfidera) in the strengths of 120 mg and 240 mg, Zydus Cadila, part of Cadila Healthcare group, said in a regulatory filing. Zydus Cadila said in its approval, the USFDA noted that Zydus …
Cipla receives final approval for generic version of Biogen IDEC Inc.’s Tecfidera® Kumar Jeetendra | September 25, 2020 Mumbai, India; September 25, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Dimethyl Fumarate DR Capsules 120mg, 240mg and 120mg/240mg Starter Pak from the United States Food and Drug Administration (US FDA). Cipla’s …
Hamdard Laboratories strengthen its medicine portfolio; launches six new Unani medicines for overall wellness Kumar Jeetendra | September 24, 2020 New Delhi, September 24, 2020: To strengthen its wellness medicine product portfolio, Hamdard Laboratories (Medicine Division), a progressive research-based health and wellness organization launched six new OTC (over the counter) medicines to treat illness like fever, cold, cough, etc. The newly launched medicines are developed from ancient Unani formulations that combine the benefits of time-tested …
India preliminaries for Russia’s ‘Sputnik-V’ antibody may start in next barely any weeks: Dr Reddy’s Kumar Jeetendra | September 22, 2020 Reddy’s Laboratories Ltd could start late-stage Indian clinical trials of Russia’s potential coronavirus vaccine within the next few months, an executive in the Indian drugmaker said on Tuesday. Indian trials of this Sputnik-V vaccine candidate, being developed by Russia’s sovereign wealth fund, will enroll 1,000-2,000 participants and also be conducted at multiple private and government …
